In this article, we will discuss Anlotinib (Therapeutic Efficacy-6). So, let’s get started.
The pathological subtype with the greatest increase in survival was ASPS, whose median PFS was 18.23 months in the anlotinib group compared with 3 months in the control group (HR = 0.14, P < 0.0001). This trial further confirmed the efficacy and safety of anlotinib in advanced STS.